Centre for Human Reproduction, Genesis Athens Clinic, Athens, Greece.
Department of Physiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Cell Transplant. 2020 Jan-Dec;29:963689720926154. doi: 10.1177/0963689720926154.
Ovarian insufficiency is described as a multifaceted issue typically encountered in the field of assisted reproduction. The three main identified diagnoses of ovarian insufficiency include premature ovarian failure (POF), poor ovarian response (POR), and advanced maternal age (AMA). Patient heterogeneity in the era of individualized medicine drives research forward leading to the emergence of novel approaches. This plethora of innovative treatments in the service of adequately managing ovarian insufficiency is called to undertake the challenge of addressing infertile patients exploring their reproductive options. This review provides an all-inclusive presentation and critical analysis on novel treatments that have not achieved routine clinical practice status yet, but have recently emerged as promising. In light of the lack of randomized controlled trials conveying safety and efficiency, clinicians are left puzzled in addressing the "how" and "for whom" these approaches may be beneficial. From ovarian injection employing platelet-rich plasma (PRP) or stem cells to artificial gametes and ovaries, ovarian transplantation, and mitochondrial replacement therapy, this descriptive review provides insight toward assisting the practitioner in decision making regarding these cutting-edge treatments. Biological mechanisms, invasiveness levels, efficiency, as well as possible complications, the current status along with bioethical concerns are discussed in the context of identifying future optimal treatment.
卵巢功能不全被描述为辅助生殖领域中常见的多方面问题。卵巢功能不全的三个主要诊断包括卵巢早衰(POF)、卵巢反应不良(POR)和高龄产妇(AMA)。在个体化医学时代,患者的异质性推动了研究的发展,导致新方法的出现。为了充分应对卵巢功能不全患者的生育选择,这一系列创新治疗方法需要迎接挑战。
本综述全面介绍和批判性分析了尚未达到常规临床实践水平但最近出现的有前途的新型治疗方法。鉴于缺乏传达安全性和效率的随机对照试验,临床医生在解决“如何”和“对谁”这些方法可能有益的问题时感到困惑。从卵巢注射富含血小板的血浆(PRP)或干细胞到人工配子和卵巢、卵巢移植和线粒体替代疗法,本描述性综述为临床医生在这些前沿治疗方法的决策提供了见解。
讨论了生物学机制、侵袭性水平、效率以及可能的并发症,根据确定未来最佳治疗方法的情况,讨论了当前的状况和生物伦理问题。